153 related articles for article (PubMed ID: 36475458)
1. Oligometastatic disease from differentiated thyroid cancer: best treatment schemes.
Colombo E; Ottini A; Licitra L
Curr Opin Oncol; 2023 Jan; 35(1):15-21. PubMed ID: 36475458
[TBL] [Abstract][Full Text] [Related]
2. Donafenib in Progressive Locally Advanced or Metastatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Results of a Randomized, Multicenter Phase II Trial.
Lin YS; Yang H; Ding Y; Cheng YZ; Shi F; Tan J; Deng ZY; Chen ZD; Wang RF; Ji QH; Huang R; Li LF
Thyroid; 2021 Apr; 31(4):607-615. PubMed ID: 32907500
[No Abstract] [Full Text] [Related]
3. An International Phase 2 Study of Pazopanib in Progressive and Metastatic Thyroglobulin Antibody Negative Radioactive Iodine Refractory Differentiated Thyroid Cancer.
Bible KC; Menefee ME; Lin CJ; Millward MJ; Maples WJ; Goh BC; Karlin NJ; Kane MA; Adkins DR; Molina JR; Donehower RC; Lim WT; Flynn PJ; Richardson RL; Traynor AM; Rubin J; LoRusso PM; Smallridge RC; Burton JK; Suman VJ; Kumar A; Voss JS; Rumilla KM; Kipp BR; Chintakuntlawar AV; Harris P; Erlichman C
Thyroid; 2020 Sep; 30(9):1254-1262. PubMed ID: 32538690
[No Abstract] [Full Text] [Related]
4. Timing of multikinase inhibitor initiation in differentiated thyroid cancer.
Brose MS; Smit J; Lin CC; Pitoia F; Fellous M; DeSanctis Y; Schlumberger M; Tori M; Sugitani I
Endocr Relat Cancer; 2017 May; 24(5):237-242. PubMed ID: 28270435
[TBL] [Abstract][Full Text] [Related]
5. Emerging Therapies for Radioactive Iodine Refractory Thyroid Cancer.
Kirtane K; Roth MY
Curr Treat Options Oncol; 2020 Feb; 21(3):18. PubMed ID: 32048061
[TBL] [Abstract][Full Text] [Related]
6. Clinical, Pathological, and Molecular Profiling of Radioactive Iodine Refractory Differentiated Thyroid Cancer.
Shobab L; Gomes-Lima C; Zeymo A; Feldman R; Jonklaas J; Wartofsky L; Burman KD
Thyroid; 2019 Sep; 29(9):1262-1268. PubMed ID: 31319763
[No Abstract] [Full Text] [Related]
7. The Treatment of Well-Differentiated Thyroid Carcinoma.
Paschke R; Lincke T; Müller SP; Kreissl MC; Dralle H; Fassnacht M
Dtsch Arztebl Int; 2015 Jun; 112(26):452-8. PubMed ID: 26205749
[TBL] [Abstract][Full Text] [Related]
8. Multikinase inhibitors for the treatment of radioiodine refractory thyroid cancer: what have we learned from the 'real-world' experience?
Costante G
Curr Opin Oncol; 2021 Jan; 33(1):3-8. PubMed ID: 33060402
[TBL] [Abstract][Full Text] [Related]
9. Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer.
Brose MS; Nutting CM; Sherman SI; Shong YK; Smit JW; Reike G; Chung J; Kalmus J; Kappeler C; Schlumberger M
BMC Cancer; 2011 Aug; 11():349. PubMed ID: 21834960
[TBL] [Abstract][Full Text] [Related]
10. Antitumour effects of apatinib in progressive, metastatic differentiated thyroid cancer (DTC).
Shi L; You Q; Wang J; Wang H; Li S; Tian R; Yao X; Wu W; Zhang L; Wang F; Lin Y; Li S
Endocrine; 2022 Oct; 78(1):68-76. PubMed ID: 35767182
[TBL] [Abstract][Full Text] [Related]
11. Optimizing therapy for radioactive iodine-refractory differentiated thyroid cancer: current state of the art and future directions.
Dadu R; Cabanillas ME
Minerva Endocrinol; 2012 Dec; 37(4):335-56. PubMed ID: 23235190
[TBL] [Abstract][Full Text] [Related]
12. Radioiodine Refractory Differentiated Thyroid Cancer.
Chan WWL; Chan S; Kwong DLW
Methods Mol Biol; 2022; 2534():243-257. PubMed ID: 35670980
[TBL] [Abstract][Full Text] [Related]
13. Peptide Receptor Radionuclide Therapy in Thyroid Cancer.
Gubbi S; Koch CA; Klubo-Gwiezdzinska J
Front Endocrinol (Lausanne); 2022; 13():896287. PubMed ID: 35712243
[TBL] [Abstract][Full Text] [Related]
14. Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma.
Rivera M; Ghossein RA; Schoder H; Gomez D; Larson SM; Tuttle RM
Cancer; 2008 Jul; 113(1):48-56. PubMed ID: 18484584
[TBL] [Abstract][Full Text] [Related]
15. Radioiodine therapy of advanced differentiated thyroid cancer: clinical considerations and multidisciplinary approach.
Giovanella L; Scappaticcio L
Q J Nucl Med Mol Imaging; 2019 Sep; 63(3):229-234. PubMed ID: 31271270
[TBL] [Abstract][Full Text] [Related]
16. OPTIMIZING LENVATINIB THERAPY IN PATIENTS WITH METASTATIC RADIOACTIVE IODINE-RESISTANT DIFFERENTIATED THYROID CANCERS.
Jasim S; Iniguez-Ariza NM; Hilger CR; Chintakuntlawar AV; Ryder MM; Morris JC; Bible KC
Endocr Pract; 2017 Oct; 23(10):1254-1261. PubMed ID: 28816536
[TBL] [Abstract][Full Text] [Related]
17. Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
Haddad RI; Bischoff L; Ball D; Bernet V; Blomain E; Busaidy NL; Campbell M; Dickson P; Duh QY; Ehya H; Goldner WS; Guo T; Haymart M; Holt S; Hunt JP; Iagaru A; Kandeel F; Lamonica DM; Mandel S; Markovina S; McIver B; Raeburn CD; Rezaee R; Ridge JA; Roth MY; Scheri RP; Shah JP; Sipos JA; Sippel R; Sturgeon C; Wang TN; Wirth LJ; Wong RJ; Yeh M; Cassara CJ; Darlow S
J Natl Compr Canc Netw; 2022 Aug; 20(8):925-951. PubMed ID: 35948029
[TBL] [Abstract][Full Text] [Related]
18. Lenvatinib: Role in thyroid cancer and other solid tumors.
Cabanillas ME; Habra MA
Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
[TBL] [Abstract][Full Text] [Related]
19. Novel Therapeutics in Radioactive Iodine-Resistant Thyroid Cancer.
Fullmer T; Cabanillas ME; Zafereo M
Front Endocrinol (Lausanne); 2021; 12():720723. PubMed ID: 34335481
[TBL] [Abstract][Full Text] [Related]
20. Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive Iodine.
Jaber T; Waguespack SG; Cabanillas ME; Elbanan M; Vu T; Dadu R; Sherman SI; Amit M; Santos EB; Zafereo M; Busaidy NL
J Clin Endocrinol Metab; 2018 Oct; 103(10):3698-3705. PubMed ID: 30032208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]